Spiradoline

Spiradoline is a drug that is classified as a kappa opioid receptor agonist. It was developed by Eli Lilly and Company in the 1980s and has been used in scientific research, particularly in studies related to pain and addiction.

Pharmacology

Spiradoline is a potent and selective kappa opioid receptor agonist. This means it binds to and activates the kappa opioid receptors in the brain and other parts of the body. Activation of these receptors can produce a variety of effects, including analgesia (pain relief), diuresis (increased urine production), and sedation. However, it can also cause side effects such as dysphoria (a state of unease or dissatisfaction) and hallucinations.

Clinical Use

Despite its potential for pain relief, spiradoline has not been widely used in clinical practice. This is largely due to its side effect profile, which includes dysphoria and hallucinations. These side effects are thought to be related to the drug's action on the kappa opioid receptors.

Research

Spiradoline has been used in scientific research to study the role of the kappa opioid receptors in pain and addiction. It has also been used as a reference drug in the development of new kappa opioid receptor agonists.

See Also

• Opioid receptor
• Kappa opioid receptor
• Eli Lilly and Company

References

Spiradoline Resources
Latest articles Most recent articles Ongoing trials	Wikipedia